Free Trial
→ Elon says the ‘S’ word (From Paradigm Press) (Ad)tc pixel Free IGXT Stock Alerts
OTCMKTS:IGXT

IntelGenx Technologies (IGXT) Stock Price, News & Analysis

IntelGenx Technologies logo
$0.17 0.00 (0.00%)
As of 10/9/2026
Compare

About IntelGenx Technologies Stock (OTCMKTS:IGXT)

View Price History Chart DataSkip Price History Chart
Advanced
1 Day 5 Days 30 Days 90 Days 1 Year
Advanced

Key Stats

Today's Range
$0.17
▼
$0.17
50-Day Range
$0.17
▼
$0.17
52-Week Range
$0.09
▼
$0.22
Volume
N/A
Average Volume
N/A
Market Capitalization
$29.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

IntelGenx Technologies Corp. is a Canadian pharmaceutical company focused on developing and manufacturing oral drug-delivery products. The company specializes in thin-film formulations designed to dissolve in the mouth, allowing medicines to be delivered buccally or sublingually without the need to swallow a conventional tablet or capsule.

Its proprietary VersaFilm technology is used to develop pharmaceutical products for prescription, over-the-counter and other healthcare applications. IntelGenx has worked on products addressing areas such as migraine treatment, pain management and neurological conditions, and has pursued partnerships and licensing arrangements to advance and commercialize its film-based formulations.

IntelGenx was established in 2006 and is headquartered in Montreal, Quebec. The company serves the pharmaceutical and healthcare markets through research, formulation development, manufacturing and commercialization activities. Its leadership has included founder and Chief Executive Officer Horst G. Zerbe, who has been associated with the company since its formation.

AI Generated. May Contain Errors.

Receive IGXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IGXT Stock News Headlines

Intelgenx Technologies (OTC:IGXT) Stock Quotes, Forecast and News Summary
August 18, 2024  |  benzinga.comhttps://www.benzinga.com/quote/IGXT
IntelGenx Technologies Corp.: IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
July 20, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-07/62778588-intelgenx-technologies-corp-intelgenx-provides-update-on-previously-announced-sale-and-investment-solicitation-process-399.htm
The AI Stock to Keep an Eye on Before Election Day (See Why)
In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he's pointing to a different company tech giants rely on to power their AI networks, one that's not yet a household name despite receiving 10 billion dollars a year in funding. The global AI market is projected to grow more than 1800 percent, reaching 5.2 trillion dollars by 2035.tc pixel
October 12 at 1:00 AM  |  Prosperity Research (Ad)
IntelGenx Provides Update on Previously Announced Sale and Investment Solicitation Process
July 19, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/07/19/2916059/0/en/intelgenx-provides-update-on-previously-announced-sale-and-investment-solicitation-process.html
IntelGenx Obtains Preliminary Efficacy Results for the ‘BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease
July 3, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/07/03/2908117/0/en/intelgenx-obtains-preliminary-efficacy-results-for-the-buena-montelukast-versafilm-phase-2a-clinical-trial-in-patients-with-mild-to-moderate-alzheimer-s-disease.html
IntelGenx Announces Initiation of the Sale and Investment Solicitation Process
June 11, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/11/2896825/0/en/intelgenx-announces-initiation-of-the-sale-and-investment-solicitation-process.html
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
May 28, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/28/2889137/0/en/intelgenx-obtains-court-approval-of-a-sale-and-investment-solicitation-process.html
IntelGenx Initiates Restructuring Proceedings Under the CCAA to Implement a Review of its Strategic Alternatives
May 17, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/17/2884508/0/en/intelgenx-initiates-restructuring-proceedings-under-the-ccaa-to-implement-a-review-of-its-strategic-alternatives.html
See More Headlines

IGXT Stock Analysis - Frequently Asked Questions

IntelGenx Technologies' stock was trading at $0.1670 at the start of the year. Since then, IGXT shares have increased by 0.0% and is now trading at $0.1670.

IntelGenx Technologies Corp. (OTCMKTS:IGXT) posted its earnings results on Thursday, November, 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.01. The business had revenue of $0.51 million for the quarter.

Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IntelGenx Technologies investors own include Pfizer (PFE), Tesla (TSLA), Advanced Micro Devices (AMD), Ford Motor (F), Rithm Capital (RITM), Rolls-Royce Holdings PLC (RYCEY) and Blink Charging (BLNK).

Company Calendar

Last Earnings
11/12/2020
Today
10/12/2026
Fiscal Year End
12/31/2026
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:IGXT
CIK
1098880
Web
www.intelgenx.com
Phone
(514) 331-7440
Fax
514-331-0436
Employees
38
Year Founded
2003

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.04 million
Price / Sales
28.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.07) per share
Price / Book
-2.39

Miscellaneous

Outstanding Shares
174,658,000
Free Float
101,214,000
Market Cap
$29.17 million
Optionable
Not Optionable
Beta
2.47

Social Links

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

This page (OTCMKTS:IGXT) was last updated on 10/9/2026 by MarketBeat.com Staff.
From Our Partners
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
My biggest prediction yet?!
James Altucher called Facebook's rise past 100 billion dollars in 2007 and Apple's run to a trillion years lat...
Paradigm Press | Sponsoredtc pixel
Palantir and Wall Street are in on it…
Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...
Monument Traders Alliance | Sponsoredtc pixel
The AI Stock to Keep an Eye on Before Election Day (See Why)
In 2019, Charles Mizrahi named Marvell Technology his top AI pick. It's since climbed 1300 percent. Now he'...
Prosperity Research | Sponsoredtc pixel
Urgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20th
Marc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...
Chaikin Analytics | Sponsoredtc pixel